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Abstract
Background:  Minocycline, a second-generation tetracycline with anti-inflammatory and anti-
apoptotic properties, has been shown to promote therapeutic benefits in experimental stroke.
However, equally compelling evidence demonstrates that the drug exerts variable and even
detrimental effects in many neurological disease models. Assessment of the mechanism underlying
minocycline neuroprotection should clarify the drug's clinical value in acute stroke setting.
Results:  Here, we demonstrate that minocycline attenuates both in vitro (oxygen glucose
deprivation) and in vivo (middle cerebral artery occlusion) experimentally induced ischemic deficits
by direct inhibition of apoptotic-like neuronal cell death involving the anti-apoptotic Bcl-2/
cytochrome c pathway. Such anti-apoptotic effect of minocycline is seen in neurons, but not
apparent in astrocytes. Our data further indicate that the neuroprotection is dose-dependent, in
that only low dose minocycline inhibits neuronal cell death cascades at the acute stroke phase,
whereas the high dose exacerbates the ischemic injury.
Conclusion: The present study advises our community to proceed with caution to use the
minimally invasive intravenous delivery of low dose minocycline in order to afford neuroprotection
that is safe for stroke.
Background
Cerebral ischemia triggers a cascade of pathophysiological
events including excitotoxicity, ionic imbalance, oxidative
and nitrosative stresses and apoptotic-like cell death
mechanisms [1-8]. To date, the thrombolytic agent tPA is
the only effective drug for acute ischemic stroke; however,
only about 2% of ischemic stroke patients benefit from
this treatment due to its limited therapeutic window [9].
There is a desperate need to develop additional neuropro-
tective strategies [10-12]. Minocycline is a promising neu-
roprotectant because if is safe, easily penetrates the CNS,
and effective in various models of acute neurological
injury.
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Cell death associated with the initial blood flow interrup-
tion and the immediately ensuing excitotoxity is abrupt,
while inflammation occurs over a long period of time
from stroke onset. Accordingly, anti-inflammatory treat-
ment is likely to extend the therapeutic window allowing
improved intervention in stroke. Indeed, minocycline, a
common tetracycline antibiotic, has been demonstrated
to provide neuroprotection against ischemic brain via the
inhibition of the inflammatory cascade [13-15]. Accumu-
lating evidence indicates that minocycline exerts neuro-
protective effects in neurodegenerative disease models,
such as Parkinson's disease, Alzheimer's disease, multiple
sclerosis, spinal cord injury, and Huntington's disease
[16-24]. Depending on the experimental injury paradigm
[19], minocycline may promote neuroprotection through
inhibition of microglial activation via p38 against NMDA
excitotoxicity [25] ischemic injury [26], NO [27], gluta-
mate [28] and MPTP excitotoxicity [17], or through sup-
pression of apoptotic cell death via Bcl-2/cytochrome c
against ischemia in kidney cells [29], heat stress in testes
[30], and NO excitotoxicity in vascular smooth muscle
[31], spinal cord injury [32] and ALS [33]. In animal mod-
els of stroke, minocycline has been reported to reduce inf-
arct volume and to attenuate behavioral deficits [34-37]
via the inhibition of microglial activity [13-15]. Overall,
the commonly postulated pathway of minocycline neuro-
protection in stroke focuses on the modulation of micro-
glial activity. However, because the acute stage of stroke
involves abrupt neuronal injury prior to inflammatory
reaction, the demonstration of minocycline protection
against the primary ischemic cell death would be of high
therapeutic interest. Moreover, whereas the inhibition of
microglial activity by minocycline against ischemia has
been shown to highly correlate with the dose [15,34-40],
the possibility of neurotoxicity of minocycline at higher
doses has only been recently recognized [41,42].
In this study, we examined direct protective effects of
minocycline on neurons and astrocytes, and also deter-
mined minocycline's toxicity profile in both in vitro and in
vivo models of stroke. The overarching theme is to provide
guidance on advancing minocycline therapy to the clinic
by assuring the safety of the drug and further understand-
ing the feasibility of a direct neuroprotective treatment in
view of the acute cell death associated with ischemic
stroke.
Results
Minocycline improves cell viability of neurons, but not 
astrocytes
Based on ATP activities (MTT assay), minocycline, at low
doses, maintained cell viability of primary cultured neu-
rons exposed to OGD (0.001 μM: 85.9 ± 13.1%, 0.01 μM:
94.4 ± 7.2%, 0.1 μM: 90.4 ± 13.0%, 1 μM: 88.2 ± 13.8%;
values hereon are expressed relative to non-OGD exposed
group) compared to vehicle treated group (0 μM: 67.1 ±
10.3%), but was toxic at high dose (100 μM: 55.1 ± 8.4%)
(F7,32 = 14.775, p < 0.0001) (Figure 1A). In contrast,
minocycline, at all doses, did not exert neuroprotective
effects on primary cultured astrocytes, and additionally
was toxic at high dose (100 μM: 49.5 ± 5.0%) compared
to vehicle-treated group (0 μM: 72.6 ± 4.3%) (F7,32 =
16.255, p < 0.0001) (Figure 1B). Similarly, Trypan blue
results mimicked those of MMT data, in that cell viability
of neurons, but not astrocytes, was maintained by low
doses of minocycline (neurons: 0.01 μM: 66.6 ± 10.9%,
0.1 μM: 87.6 ± 2.9%, 1 μM: 77.3 ± 8.2%), while high dose
minocycline was toxic to both neurons and astrocytes
(neurons: 100 μM: 10.5 ± 4.7%; astrocytes: 100 μM: 43.3
± 7.7%) compared to vehicle-treated group (neurons: 0
μM: 56.3 ± 6.9%, F7,32 = 57.300, p < 0.0001, astrocytes: 0
μM: 43.3 ± 7.7%, F7,32 = 27.989, p < 0.0001) (Figure 1C-
L).
Minocycline alters OGD-induced apoptotic cell death
The cell death of neurons and astrocytes under OGD con-
dition represents apoptotic-like cell damage as revealed by
caspase 3/7 assay (neurons: 29927.5 ± 6365.4/well; astro-
cytes: 17758.5 ± 5.78.9 well) (Figure 2A, B) and TUNEL
assay (neurons: 189.6 ± 18.8 cells/0.2 mm2; astrocytes:
60.7 ± 2.8 cells/0.2 mm2) (Figure 2I, J). Compared to nor-
mal, non-OGD conditions, OGD increased caspase activ-
ity levels by about 1.5-fold. Treatment with low dose
minocycline prevented such apoptotic-like cell death in
neurons characterized by reduced caspase 3/7 activity
(neurons: 16675.8 ± 2474.2/well) (F2,12 = 19.611; p =
0.0002) (Figure 2A) and decreased TUNEL positive cells
(55.0 ± 13.2 cells/0.2 mm2) (F2,12 = 13.26; p < 0.001) (Fig-
ure 2C-E, I). However, protective effects of low dose mino-
cycline were not detected in astrocytes (caspase: 22705.9
± 2268.0/well, TUNEL: 83.7 ± 4.544 cells/0.2 mm2) (Fig-
ure 2B, F-H, J). Moreover, minocycline, at a high dose,
worsened apoptotic-like cell death in both neurons (cas-
pase: 35600.0 ± 3450.4/well), (TUNEL: 234.0 ± 33.7
cells/well) and astrocytes (caspase: 30708.0 ± 2901.3/
well) (F2,12 = 9.831; p = 0.0030), (TUNEL: 75.8 ± 10.5
cells/0.2 mm2) (F2,12 = 4.76; p < 0.01) (Figure 2A, B, I, J).
Under OGD condition, increased Bcl-2 expression was
induced by low dose minocycline in cultured neurons (0
μM: 1.25 ± 0.48, 1 μM: 18.9 ± 2.16 cells/0.05 mm2), but
not at a high dose (100 μM: 2.21 ± 1.10 cells/0.05 mm2)
(F2,12 = 15.288; p = 0.004) (Figure 3A-D, H). In contrast,
Bcl-2 expression was not altered by minocycline at all
doses in astrocytes (0 μM: 3.33 ± 2.11, 1 μM: 1.67 ± 1.67,
100 μM: 0.0 ± 0.0 cells/0.05 mm2) (Figure 3A, E-G, I). In
parallel, the OGD-induced release of cytochrome c from
mitochondria into cytosol was prevented by minocycline
at a low dose in neurons.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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ATP activity and trypan blue assay in cultured neurons and astrocytes Figure 1
ATP activity and trypan blue assay in cultured neurons and astrocytes. ATP activity was measured to reveal cell via-
bility with varying concentrations of minocycline or vehicle. OGD condition reduced ATP activity of cultured neurons to 40% 
of non-OGD control group (A). Low doses of minocycline (0.001 to 10 μM) preserved cell viability of neurons (A), but not 
astrocytes (B). In contrast, high dose of minocycline (100 μM) displayed toxicity to both neurons and astrocytes (A, B). In par-
allel with ATP assay, Trypan blue assay revealed that low doses of minocycline (0.001-10 μM) exerted neuroprotective effects 
on cultured neurons, but not astrocytes (C-G: neurons, H-L: astrocytes, C, H: non-OGD control, D, I: 0 μM, E, J: 1 μM, F, K: 
100 μM of minocycline). High dose of minocycline (100 μM) displayed toxicity for both neurons and astrocytes. Data are 
shown as mean values ± SEM (*p < 0.05 increase and **p < 0.05 decrease vs. vehicle-treated cultured neurons or astrocytes; A, 
G: neurons, B, L: astrocytes). Scale bar: 25 μm.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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Caspase3/7 activity and tunel staining in cultured neurons and astrocytes Figure 2
Caspase3/7 activity and tunel staining in cultured neurons and astrocytes. Low dose minocycline (1 μM) reduced 
caspase3/7 activity of neurons (A), but not of astrocytes (B). In contrast, high dose minocycline (100 μM) displayed no suppres-
sive effects on caspase 3/7 activity of neurons and increased that of astrocytes (A, B). Similarly, low dose minocycline reduced, 
whereas high dose minocycline increased the number of TUNEL positive neurons compared to vehicle-treated cultured neu-
rons (OGD-exposed neurons treated with 0, 1 and 100 μM of minocycline; panels C, D and E, respectively). On the other 
hand, minocycline at all doses did not reduce the number of TUNEL positive astrocytes (OGD-exposed astrocytes treated 
with 0, 1 and 100 μM of minocycline; panels F, G and H, respectively). Data are shown as mean values ± SEM (*p < 0.05. A, I: 
neurons, B, J: astrocytes). Scale bar: 50 μm.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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Bcl-2 expression and cytochrome c release in cultured neurons and astrocytes Figure 3
Bcl-2 expression and cytochrome c release in cultured neurons and astrocytes. Western blotting revealed that low 
dose minocycline upregulated Bcl-2 expression of neurons (A: lysates from 0, 1 and 100 μM of minocycline-treated neurons 
correspond to lanes 1, 2, and 3, respectively) with subsequent inhibition cytochrome c release from mitochondria to cytosol 
(B: lysates from 0, 1 and 100 μM of minocycline-treated neurons correspond to lanes 7, 8, and 9, respectively). In contrast, 
minocycline at all doses did not upregulate Bcl-2 expression in astrocytes (A: lysates from 0, 1 and 100 μM of minocycline-
treated astrocytes correspond to lanes 4, 5, and 6, respectively). Immunocytochemical analysis revealed that minocycline low 
dose (D: 1 μM) significantly increased the number of Bcl-2 positive neurons compared to vehicle-treated (C: 0 μM) or high 
dose-treated neurons (E: 100 μM). In contrast, minocycline at all doses did not alter the number of Bcl-2 positive astrocytes (F: 
0 μM, G: 1 μM and H: 100 μM). Quantitative analyses of Bcl-2 positive cells are shown in panels I and J. Data represent mean 
values ± SEM (* p < 0.05. I: neurons, J: astrocytes). Scale bar: 25 μm.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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Minocycline ameliorates stroke-induced behavioral 
deficits
At three days post-stroke, the typical motor and neurolog-
ical dysfunctions produced by MCAo were significantly
blocked by minocycline when intravenously adminis-
trated at a low dose (20 mg/kg) starting at 60 minutes
after reperfusion, as revealed by EBST (0 mg/kg: 88 ±
12.5%, 20 mg/kg: 68.3 ± 15%) (F2,27  = 10.439; p =
0.0004) (Figure 4A) and Bederson test (0 mg: 1.67 ± 0.14,
20 mg/kg: 1.16 ± 0.36) (Kruskal-Wallis H value = 19.2, df
= 2, p < 0.0001) (Figure 4B). In contrast, MCAo stroke ani-
mals treated with high dose minocycline (100 mg/kg) dis-
played neurological deficits (Bederson: 2.15 ± 0.38) that
were significantly worse and their motor deficits were
slightly exacerbated (EBST: 89 ± 13%; though not signifi-
cant difference) compared to stroke animals that received
vehicle alone. In addition, these stroke animals treated
with high dose minocycline performed significantly worse
in both behavioral tests than those that received the low
dose minocycline (p's < 0.05).
Minocycline reduces cerebral infarcts
Following behavioral testing at three days post-stroke,
TTC staining revealed that the infarct volume was signifi-
cantly reduced by low dose minocycline (80.1 ± 41.7
mm3) relative to vehicle-treated stroke group (138.5 ±
48.8 mm3) (F2,27 = 9.552; p = 0.0007) (Figure 5A, B, D).
In particular, the stroke damage within the striatum was
significantly smaller in low dose minocycline-treated
stroke animals than vehicle-treated stroke animals. In
contrast, the infarct volume in high dose minocycline-
treated stroke group was significantly larger than those of
vehicle-treated stroke group (180.47 ± 56.1 mm3) (Figure
5A, C, D). Indeed, in some high dose minocycline-treated
stroke animals, cerebral infarcts were observed even in the
hemisphere contralateral to the MCAo side. Posthoc anal-
yses of hemorrhage revealed 20% incidence with an aver-
age size of 12 mm2, which did significantly differ across
treatment groups. Similarly, measurements of edema
found no significant differences across groups (although
there was a slight reduction in the low dose minocycline
group compared to vehicle group), indicating that our
analysis of neuronal cell loss (see below) was not affected
by edema formation.
Minocycline abrogates MCAo-mediated apoptotic cell 
death
A new set of animals (n = 18) underwent MCAo, ran-
domly assigned to similar minocycline treatment as
described above, and euthanized at three days post-stroke
for immunohistochemical analyses of apoptotic cell
death. Results revealed that Bcl-2 immunoreactivity was
significantly increased in the brains of stroke animals that
were treated with low dose minocycline, especially within
the striatum ipsilateral to the occluded MCA (20 mg/kg:
9.83 ± 1.50 density/0.05 mm2) relative to vehicle-treated
stroke animals (0.235 ± 0.112 cells/0.05 mm2) (F2,15 =
37.151; p < 0.0001) (Figure 6A, B, D). In contrast, Bcl-2
immunoreactivity in the same striatal area of high dose
minocycline-treated stroke animals was not significantly
differrent from vehicle-treated stroke animals (100 mg/kg:
1.14 ± 0.22 density/0.05 mm2) (Figure 6A, C, D). To clar-
Motor and neurological performance of stroke rats Figure 4
Motor and neurological performance of stroke rats. Both motor and neurological dysfunctions were significantly amel-
iorated by low dose minocycline (20 mg/kg, i.v.), as revealed by elevated body swing test (EBST; A) and Bederson test (B). In 
contrast, high dose minocycline (100 mg/kg, i.v.) significantly exacerbated neurological deficits and slightly worsened motor def-
icits. Data are shown as the mean values ± SEM (*p < 0.05).BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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ify which cell type expresses Bcl-2, we examined double-
labeling of Bcl-2 with MAP2 or GFAP by immunohisto-
chemistry in ischemic striatal peri-infact area of each
group. Bcl-2 was found co-localized with MAP2 in all
groups (Figure 6F-H). In contrast, GFAP positive astro-
cytes did not express Bcl-2 (Figure 6I-K). These results sug-
gest that low dose minocycline can exert anti-apoptotic
effects via Bcl-2 upregulation in ischemic neurons. A few
cells in vehicle-treated stroke rats also expressed Bcl-2 and
MAP2 double-labeling, indicating that ischemia alone,
without any treatment intervention, might slightly induce
the expression of Bcl-2 in neurons.
In addition, whereas TUNEL-positive cells with aggluti-
nated nuclei highly populated the striatal peri-infarct area
of high dose minocycline treated or vehicle treated ani-
mals, there were significantly fewer TUNEL-positive cells
in animals treated with low dose minocycline (F2,15 =
35.411; p < 0.0001) (Figure 7A-D). Similar dose depend-
ent anti-apoptotic effects were obtained from Bcl-2 immu-
nohistochemistry, in that low dose minocycline
significantly increased the number of Bcl-2 positive cells
within the striatal peri-infarct area compared to high dose
minocycline or vehicle treatment.
Minocycline rescues neurons in the peri-infarct area
To determine the effect of minocycline on neurons in vivo,
we examined the number of Nissl positive cells in
ischemic peri-infarct area on consecutive brain sections.
Vehicle-treated MCAo stroke rats exhibited neuronal cell
loss in the peri-infarct area (152.0 ± 10.0 cells/0.05 mm2)
relative to intact brain (303.3 ± 13.9 cells/0.05 mm2) (Fig-
ure 8A, B, E). Low dose minocycline (228.3 ± 6.9 cells/
0.05 mm2) revealed significant protective effect relative to
vehicle treated group (152.0 ± 10.1 cells/0.05 mm2) (F3,16
= 4 9.488; p < 0.0001) (Figure 8B, C, E), as well as retained
fundamental structure of striatum. In contrast, high dose
minocycline (104.3 ± 6.8 cells/0.05 mm2) revealed signif-
icant neuronal cell loss (104.3 ± 16.4 cells/0.05 mm2) rel-
ative to vehicle treated group (though no significant
difference), in addition to dissolution of fundamental
structure of striatum with severe edema (Figure 8B, D, E).
Discussion
The present study demonstrates that minocycline exerted
direct protection on neurons, in the absence of astrocyte
participation, against ischemic stroke. An equally impor-
tant finding is that minocycline not only promoted dose-
dependent neuroprotective effects, but also induced toxic-
ity at a high dose for both neurons and astrocytes. Both
sets of in vitro and in vivo studies corroborated such neu-
roprotection and toxicity profile of minocycline. In addi-
tion, in vitro mechanistic studies revealed that a major
therapeutic pathway, by which minocycline prevented the
ischemic cell death, is via an anti-apoptotic mechanism.
Parallel in vivo data showed that low dose, but not high
dose, minocycline attenuated stroke-induced behavioral
deficits, decreased apoptotic cell death and reduced cere-
bral infarction. The intravenous route and the post-stroke
delivery further advance the utility of minocycline in the
clinic.
Cerebral infarct analysis of stroke brains Figure 5
Cerebral infarct analysis of stroke brains. TTC staining 
revealed that low dose minocycline (20 mg/kg; B) significantly 
reduced cerebral infarct volumes compared to the vehicle 
group (A). In particular, the striatal infarct volumes in the low 
dose group were significantly smaller than the vehicle group. 
In contrast, high dose minocycline (100 mg/kg; C) significantly 
increased the infarct volumes compared to those in the vehi-
cle group. Quantitative analyses are shown in panel D. Data 
represent mean values ± SEM (*p < 0.05).BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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Tunel staining in the ischemic peri-infarct area Figure 6
Tunel staining in the ischemic peri-infarct area. Low dose significantly decreased (B), whereas high dose significantly 
increased (C) the number of TUNEL positive cells in the ischemic striatal peri-infarct area of minocycline-treated stroke rats 
compared to the vehicle-treated stroke rats (A). Quantitative analyses of Bcl-2 positive cells are shown in panel D. Data are 
shown as mean values ± SEM (*p < 0.05). Four representative ischemic striatal peri-infarct areas (+0.2 mm anterior to the 
bregma), in which TUNEL positive cells were counted (data in panel D), are shown in panel E (square boxes labeled 1-4 corre-
spond to areas 1-4 in panel D). Scale bar: 25 μm.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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To date, the primary CNS mechanism implicated in mino-
cycline neuroprotection is the drug's highly potent inhib-
itory effect on microglial activation, which is achieved by
blocking the phosphorylation of p38 and the transloca-
tion of 5-Lipoxygenase into the nucleus, thereby prevent-
ing the release of cytokines and the induction of
inflammation [15,40,43-45]. On the other hand, recent
evidence has shown that minocycline in the periphery
affords protective effects on kidney cells against ischemia
via the apoptotic Bcl-2/cytochrome c pathway [29]. We
report here that minocycline also promoted protection
against ischemia in the CNS by arresting apoptotic Bcl-2/
cytochrome c pathway. In our in vitro OGD condition, cul-
tured neurons and astrocytes underwent apoptosis-like
cell death as revealed by induction of caspase 3/7 activity
and DNA fragmentation (TUNEL positive cells). Treat-
ment with low, but not high dose minocycline abrogated
apoptosis characterized by reduced caspase 3/7 activity
and decreased number of TUNEL positive cells. Of note,
such blockade of OGD-induced apoptosis by low dose
minocycline only occurred in cultured neurons and was
not evident in cultured astrocytes.
In stroke brains, increased chemokine mRNA expression
displays a biphasic profile, being found initially in neu-
rons, then subsequently in astrocytes [46]. Of interest,
high levels of chemokines were found in areas of gliosis
surrounding recent infarcts [47-49] and correlated with
the accumulation of macrophage/microglia in the
ischemic lesion, suggesting chemokine's role in the
Bcl-2 expression in the ischemic peri-infarct area Figure 7
Bcl-2 expression in the ischemic peri-infarct area. Low dose (B) significantly upregulated, whereas high dose (C) signifi-
cantly suppressed the Bcl-2 expression in the ischemic peri-infarct area of minocycline-treated rats compared to that in the 
vehicle-treated rats (A). Quantitative analyses of Bcl-2 positive cells are shown in panel D. Data are shown as mean values ± 
SEM (*p < 0.05). Two representative ischemic striatal peri-infarct areas (+0.2 mm anterior to the bregma), in which Bcl-2 pos-
itive cells were counted (data in panel D), are shown in panel E (square boxes). Co-localization of Bcl-2 and MAP2 was found 
in ischemic striatal peri-infarct area, suggesting anti-apoptotic effects of minocycline via Bcl-2 upregulation in ischemic neurons 
(F-H). In contrast, GFAP positive astrocytes did not express Bcl-2 (I-K). Scale bar: 25 μm (A-C), 12.5 μm (F-K); asterisks (*): 
merged cell; green and red immunofluorescent markers correspond to Bcl-2 and MAP2, respectively.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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Neuronal survival in the ischemic peri-infarct area Figure 8
Neuronal survival in the ischemic peri-infarct area. Neuronal survival in the ischemic striatal peri-infarct area, visualized 
with cresyl violet stain, was significantly preserved by low dose minocycline (A: intact control, B: vehicle, C: 20 mg/kg, D: 100 
mg/kg). In contrast, high dose minocycline resulted in the collapse of fundamental neuroarchitecture of the striatum accompa-
nied by severe edema. Data are shown as mean values ± SEM (*p < 0.05). Scale bar: 25 μm.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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recruitment of inflammatory cells into the brain in
response to stroke [49-52]. Based on the above observa-
tions, suppressing chemokine elevation during its initial
onset in neurons, before astrocytes become involved in
this inflammation-ischemia-triggered secondary cell
death, may provide better therapeutic outcome than treat-
ment regimen targeting astrocytes. Although in recent
years enhancing astrocyte survival has been suggested as
an alternative protective approach against ischemic dam-
age [53,54], therapeutic strategies that confer direct neu-
ronal protection are likely to improve clinical prognosis.
The present results indicate that minocycline, in addition
to its established anti-microglial activity, could directly
protect neurons via an anti-apoptotic mechanism.
To further clarify the anti-apoptotic features of minocy-
cline, we examined the alterations in expression of apop-
tosis-related components, specifically the cell survival-
enhancing Bcl-2/cytochrome c pathway. Our results
revealed that low dose minocycline protected again neu-
rons, but not astrocytes against OGD by elevating Bcl-2
expression and consequently strengthening the anchor of
cytochrome c to the mitochondria. We extend here the
participation of Bcl-2/cytochrome c pathway in minocy-
cline's direct protection of OGD-exposed neurons, previ-
ously shown in ischemic kidney cells [29].
To reveal the possible toxic side effects of minocycline, we
similarly examined cell survival and apoptosis in OGD-
exposed cultured neurons and astrocytes treated with high
dose (100 μM) minocycline. Minocycline at a high dose
was toxic as revealed by markedly reduced cell survival of
both OGD-exposed neurons and astrocytes compared to
vehicle treated OGD-exposed cells. Moreover, relative to
vehicle treated OGD exposed cells, high dose minocycline
did not elevate Bcl-2 expression, but increased caspase 3/
7 activity, as well as the number of TUNEL positive cells in
the ischemic striatum.
In parallel to the toxicity profile of minocycline observed
in the in vitro OGD condition, high dose minocycline
exacerbated both behavioral and histological deficits in
stroke animals. In contrast, low dose minocycline
increased Bcl-2, but decreased TUNEL positive cells in the
ischemic peri-infarct area. Moreover, low dose minocy-
cline-treated animals exhibited a pattern of Bcl-2 expres-
sion that was only found in neurons, but not in astrocytes,
further supporting the neuroprotective mechanism
whereby minocycline exerted anti-apoptotic effects
directly on neurons.
In previous reports, therapeutic efficacy in different ani-
mal models of neurological disorders was consistently
observed when minocycline was administered 3 mg/kg-
45 mg/kg either intravenously or intraperitoneally [37-
39]. Recent studies have suggested that depending on the
animal species (i.e., mice), minocycline may confer neu-
rotoxicity in experimental ischemia [19,38,42] and Par-
kinson's disease [41]. These reports and the present data,
taken together, further clarified the toxicity profile of
minocycline highlighting critical factors including type of
cell line (for in vitro studies), experimental injury para-
digm, and dosage, as well as delivery route of minocycline
[19,37-39].
The observed dose-dependent protection of neurons over
astrocytes by low dose minocycline, and the neurotoxic
effects of high dose minocycline provide guidance in
designing the clinical protocol for stroke patients. Because
astrocytes play a crucial role in blood brain barrier main-
tenance, a perturbed astrocyte viability, as seen with high
dose minocycline, may compromise the barrier that could
allow inflammatory cells to penetrate the CNS and exacer-
bate the stroke deficits. Indeed, most of the animals that
received high dose minocycline exhibited severe edema.
The establishment of an effective dose range that confers
protection on neurons, while not disrupting astrocytes,
would perhaps lead to improved therapeutic outcome of
minocycline.
Minocycline's inability to protect astrocytes or to increase
Bcl-2 expression in these cells in vitro seems to be the most
original finding of this study. Our approach to use low
doses and high doses to show minocycline's protection
versus toxicity in the same in vitro and in vivo stroke mod-
els is clinically relevant since the drug is already in clinical
trials. At first glance, the choice for the present high doses
of minocycline (100 μM or 100 mg/kg) would seem
extremely high, considering that in a clinical trial [21]
multiple sclerosis patients who received orally 200 mg
minocycline daily dose (equals 2.85 mg/kg for 70 kg per-
son, serum levels reach maximum of 4 mg/l = 8 uM) dur-
ing a 6-month period exhibited no observable significant
side effects. However, our recent study clearly demon-
strates that a 3 mg/kg intravenous dose of minocycline is
required to obtain serum levels in rats similar to that
achieved in humans after a standard 200 mg dose [37],
suggesting differences in the drug metabolism between
rats and humans. Accordingly, the rationale for selecting
the present doses of minocycline is based on our studies
[37,39] and those of others [13,28,34,55,56] indicating
that these doses correspond to the clinically relevant doses
of minocycline in stroke rodent models. In addition, we
extended the high dose range to reveal the toxicity profile
of minocycline. Indeed, a multiple high dose minocycline
injection regimen, involving subcutaneous 135 mg/kg
over 2 days followed by 68 mg/kg over the succeeding two
days, was recently shown to exacerbate the striatal damage
produced by hypoxic-ischemic injury in rats [42].
Depending on the dose and route of delivery, discordant
results and conclusions accompany the actions of minoc-
ycline in various stroke and neurodegeneration models.BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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The present data underscore that the minocycline dose is
critical as it might attenuate or worsen the stroke out-
come. While many studies have pursued intraperitoneal
or subcutaneous injections of high dose minocycline in
order to promote neuroprotection, we show here that
robust neuroprotective effects in acute stroke can be
achieved with intravenous low dose minocycline, thereby
circumventing the toxicity now increasingly being recog-
nized with high dose minocycline. This neuroprotective
action of low dose minocycline at a clinically suitable dos-
ing regimen advances the entry of this drug for phase I
human stroke trials. In view of a recent clinical trial show-
ing that the relatively high dose of 400 mg/day for 9
months minocycline led to an accelerated deterioration in
the amyotrophic lateral sclerosis functional rating scale,
accompanied by gastrointestinal and neurological adverse
events [57], a more careful consideration of minocycline
dose is indicated as similarly shown in the present study.
Conclusion
In conclusion, the safety and therapeutic efficacy of low
dose minocycline and its robust neuroprotective effects
during acute ischemic stroke make it an appealing drug
candidate for stroke therapy. The implication of the
present direct minocycline protection of neurons, as
opposed to the reported inhibition of microglial activity,
can be best appreciated by the fact that stroke triggers
abrupt neuronal cell death that would require immediate
intervention to rescue ischemic cells. A delay in abrogat-
ing the primary stroke-induced cell death could result in
"fixed" or devastating histological and functional deficits
that will be difficult to repair. Coupled with the ability of
minocycline to block the microglial activation occurring
at later post-stroke periods, we now provide evidence that
minocycline is also able to achieve an expedited direct
neuroprotection against ischemia at early time points. To
our knowledge, such two-pronged neuroprotective
approach targeting both primary and secondary cell death
processes associated with stroke has not been shown with
monotherapy. Minocycline stands as a multiple site of
action therapeutic drug, which clinically should be effec-
tive in treating neurological diseases, like stroke, charac-
terized by many facets of cell death cascades.
Methods
The present experimental research and relevant ethical
issues were approved by Veterans Affair Medical Center
Institutional Animal Care and Use Committee, and
adhered to National Institutes of Health guidelines.
In vitro study
Cell culture
Primary cultures of neurons and astrocytes were derived
from the rat (Sprague-Dawley) striatum and maintained
in culture following the supplier's protocol (CAMBREX,
MD). Briefly, immediately after thawing, cells (4 × 104
cells/well) were seeded and grown in 96-well plate coated
by poly-l lysine in Neurobasal media (GIBCO, CA) con-
taining 2 mM L-glutamine, 2% B27 (GIBCO, CA) and 50
U/ml penicillin and streptomycin for 7-10 days at 37°C in
humidified atmosphere containing 5% CO2. Purity of the
cells were immunocytochemically determined to be >
99% for both neuronal and astrocytic cell population as
revealed by DARPP-32 and GFAP immunostaining,
respectively. Moreover, we confirmed that these cells were
appropriate for the oxygen glucose deprivation (OGD)
injury model, where glutamate excitotoxicity plays an
important role, as revealed by expression of glutamate
receptors (determined immunocytochemically using
vesicular glutamate transpoter-1) in 50% of the neuronal
and astrocytic cell population.
Oxygen-glucose deprivation (OGD)
Cultured cells were exposed to the OGD injury model as
described previously [58] with few modifications. Briefly,
culture medium was replaced by a glucose-free Earle's bal-
anced salt solution (BSS) with the following composition
(116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 1 mM
NaH2PO4, 26.2 mM NaHCO3, 0.01 mM glycine, 1.8 mM
CaCl2, and pH adjusted to 7.4 with or without minocy-
cline. Cultured cells were placed in humidified chamber,
then equilibrated with continuous flow of 92% N2 and
8% O2 gas for 15 minutes. After this equilibrium, the
chamber was sealed and placed into the incubator at 37°C
for 75 minutes, 2 hours, 4 hours and 12 hours for Western
blot, caspase assay, MTT assay and Trypan blue stain,
respectively. For Western blot, cells were subsequently
exposed to standard medium in 5% CO2 incubator for an
additional 6 hours to generate apoptosis-related proteins
[58].
Cell viability
Cell viability was evaluated by ATP activity following the
supplier's protocol (Promega, WI) and by Trypan blue
(Sigma, MO). Briefly, MTT assay was carried out by adding
MTT assay solution immediately after OGD. The intensi-
ties of chemiluminescence of ATP activity were measured
and calculated by Image station 2000R system (Kodak,
NY). In addition, Trypan blue exclusion method was con-
ducted and mean viable cell counts were calculated in
three randomly selected areas (0.2 mm2) in each well (n =
5 per treatment condition) to reveal the cell viability for
each treatment condition.
Caspase 3/7 assay
For caspase assay, the same number of cells (40,000 cells/
well) was seeded in 96-well plate and maintained as
described above. After OGD treatment for 2 hours, cas-
pase 3/7 assay was examined following the manufac-
turer's protocol (Promega, WI). Briefly, examination of
caspase activity was performed by adding caspase assay
solution immediately after OGD. Following incubation atBMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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room temperature, the intensities of chemiluminescence
were measured and calculated following the procedures
mentioned above. The intensities were compared between
minocycline-treated and vehicle-treated OGD groups after
subtracting the mean of no OGD control group.
Immunoblotting
For Western blot of Bcl-2, cultured cells were extracted and
homogenized by solution containing 20 mM Tris-HCl
(7.6), 150 mM NaCl, 1% NP40, 1 mM PMSF, 1 μg/ml leu-
peptin, 1 μg/ml TPCK and 1 μg/ml TLCK. For cytochrome
c assay, cultured cells were extracted following the manu-
facturer's protocol (BioVision, CA). Briefly, cells were
homogenized in ice-cold buffer containing protease
inhibitors. After centrifugation at 700 g for 10 minutes at
4°C, the supernatant was further centrifuged at 12,000 g
for 40 minutes at 4°C. Thereafter, the supernatant was
collected as cytosol fraction, and the pellet was resus-
pended with mitochondria extraction buffer containing
DTT and protease inhibitor, and stored as mitochondria
fraction. Collected samples (50 μg) were loaded into
12.5% SDS-PAGE electrophoresis and transferred to a
nitrocellulose membrane. After blocking by 3% skim milk
in 10 mM Tris-HCl (pH 7.6), 150 mM NaCl and 0.3% Tri-
tonX at room temperature for one hour, the blot was
probed with a monoclonal antibody against Bcl-2
(1:2000, Chemicon, CA), and cytochrome c (1:500, Phar-
migen, CA), and visualized using a HRP-conjugated anti-
mouse IgG antibody and chemiluminescence system
(Amersham, UK).
Immunocytochemistry
Each 1 × 105 cells were plated on 8 well Permanox® slides
(Nalge Nunc Int, IL) at two days before fixation. Cultured
cells were treated with 4% paraformaldehyde (PFA) for 10
minutes at room temperature after rinsing with phosphate
buffered saline (PBS). After blocking reaction with 10%
normal goat serum (Vector, CA), cells were incubated
overnight at 4°C with an anti-Bcl-2 monoclonal antibody
(1:100, Chemicon, CA), or anti-MAP2 polyclonal anti-
body (1:1000, Chemicon) with 10% normal goat serum.
After several rinses in PBS, cells were incubated for 45
minutes at room temperature in FITC-conjugated anti-
mouse IgG (1:1000, Molecular probe, CA), or Rhodam-
ine-conjugated anti-rabbit IgG (1:2000, Molecular probe,
CA) for visualization. Cells were processed for DAPI.
immunostaining then subsequently embedded with
mounting medium. Immunofluorescent images were vis-
ualized using Zeiss Axiophot 2 and the number of immu-
nopositive cells was counted per high power field view
selected at random (50,000 μm2). In addition, control
studies included exclusion of primary antibody and sub-
stituted with 10% normal goat serum in PBS. No immu-
noreactivity was observed in these controls. All studies
were conducted in quadruplicates, with n = 100 per treat-
ment condition. Assessments were performed blindly by
an independent investigator.
TUNEL staining
Cultured cells were washed with PBS. As described in our
previous report [59], the TUNEL staining was carried out
with DNA fragmentation detection kit (Roche, Man-
nheim, Germany), which detects double-strand breaks in
genomic DNA with diaminobenzidine. The number of
TUNEL positive cells was counted per high power field
view selected at random (200,000 μm2) via Zeiss Axio-
phot 2.
In vivo study
Stroke surgery
Sprague-Dawley, male 10-week old rats, weighing about
250 g, were anesthetized with gas inhalation composed of
30% oxygen (0.3 L/min) and 70% nitrous oxide (0.7 L/
min) mixture. The gas was passed through an isoflurane
vaporizer set to deliver 3% to 4% isoflurane during initial
induction and 1.5% to 2% during surgery. Transient uni-
lateral focal ischemia was produced using a well-estab-
lished middle cerebral artery occlusion (MCAo) using the
intraluminal suture model as previously described
[53,60]. Physiological parameters, via blood gas assays
(using the tail vein for sampling), and ischemia and reper-
fusion levels determined by Laser Doppler measurements,
did not differ across all MCAo stroke groups. The body
temperature of animals was maintained at 37°C during
the surgery until they recovered from anesthesia. Based on
our pilot studies, a 30-minute MCAo produces a well-
delineated striatal penumbra with minimal necrotic
region. Laser Doppler was used during the 30-minute
occlusion period to verify reduction in blood flow, with
the probe placed on the dura using rostro-caudal and lat-
eral coordinates (AP: +2.0, ML: ± 2.0) relative to bregma.
Insertion of the intraluminal filament led to 80% or
greater reduction in cortical blood flow, which was used
as criterion for inclusion of animals to the study and their
subsequent random assignment to the treatment groups.
TTC staining at 24 hours after MCAo revealed a small stri-
atal infarct core with sparing of much of the striatum and
cortex. Ischemic damage progressed beyond this time
point and by 72 hours post-stroke the infarct included
more striatal tissue and a substantial amount of cortex.
The term "peri-infarct" is subsequently used here to refer
to the tissue adjacent which became incorporated into the
infarct beyond the 24-hour period. The mortality rate for
the present MCAo study was 3 animals from original 33
animals, which equate to about 10%; these animals died
immediately after stroke surgery. Minocycline doses of 20
mg/kg or 100 mg/kg in 5 ml saline or vehicle were admin-
istered intravenously (via the jugular vein) as a single
bolus at 60 minutes after the reperfusion. This dosing reg-
imen of minocycline was based on our previous papers
[29,37].BMC Neuroscience 2009, 10:126 http://www.biomedcentral.com/1471-2202/10/126
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Behavioral tests
Behavioral estimation was performed by using semi quan-
titative analysis of motor asymmetry (elevated body swing
test, EBST) and neurological function (Bederson test) at
72 hours just prior to euthanasia as previously described
[60-62]. The analyses of Bederson data were from raw
individual scores generated from a scale of 0-3, in the
order of severity of impairments. To prevent any exam-
iner's bias, all behavioral evaluations were performed by
an investigator blinded to the treatment conditions.
Infarct estimation via 2,3,5-triphenyltetrazolium chloride (TTC) 
staining
After behavioral testing at 72 hours post stroke, animals
were anesthetized with a lethal dose of equithesin (500
mg/kg, i.p.), decapitated and the brains harvested. Histo-
logical determination of infarct volume was performed
using standard TTC staining, and quantitative image anal-
ysis was carried out as previously described [63-65]. Inf-
arct volume (mm3) was determined using the following
formula = 2 mm (thickness of the section) × [sum of the
infarction area in all brain section (mm3)]. To minimize
artifacts produced by postischemic edema in the infarcted
area, the infarction area in the ipsilateral hemisphere was
indirectly measured by subtracting the noninfarcted area
in the ipsilateral hemisphere from the total intact area of
the contralateral hemisphere. However, because edema
extends beyond the border of the infarct, into peri-infarct
tissues, the 72-hour time point of TTC assay might have
likely represented maximum edema as brain swelling
caused by focal ischemia started to resolve beyond this
time point. Because cell densities are based on cell counts
within a defined area, the results are likely to have been
influenced by edema.
Immunohistochemistry
Under deep anesthesia, rats were sacrificed at 72 hours
after reperfusion, and perfused through the ascending
aorta with 200 ml of cold PBS, followed by 100 ml of 4%
PFA in PBS. Brains were removed and post-fixed in the
same fixative for 3 days followed by 30% sucrose in phos-
phate buffer (PB) for 1 week. Six series of coronal sections
were cut at a thickness of 30 μm by cryostat and stored at
-20°C. Free floating sections for immunohistochemistry
were incubated overnight at 4°C with an anti-Bcl-2 mon-
oclonal antibody (1:50, Chemicon), anti-MAP2 polyclo-
nal antibody (1:500, Chemicon), or anti-GFAP polyclonal
antibody (1:500, Chemicon, CA) with 10% normal goat
serum. After several rinses in PBS, the sections were visu-
alized following the method described above with modi-
fication to accelerate FITC with biotin conjugated anti-
mouse IgG antibody and FITC conjugated streptoavidin
(1:500, Sigma, MO). Control studies included exclusion
of primary antibody substituted with 10% normal goat
serum in PBS. No immunoreactivity was observed in these
controls. Furthermore, TUNEL staining was performed as
described in in vitro section, using DNA fragmentation
detection kit (Roche, Mannheim, Germany). Finally,
brain sections were counterstained with cresyl violet stain.
Immunofluorescent and light microscopy were carried
out using Zeiss Axiophot 2. Sections were blind-coded
and Abercrombie's formula [66] was used to calculate the
total number of immunopositive cells.
Morphological Analysis
The density of the Bcl-2 positive cells and TUNEL positive
cells in the ischemic peri-infarct area (determined by cre-
syl violet stain using consecutive sections) was estimated
and analyzed as described previously [67]. Briefly, the
level of +0.2 mm anterior to the bregma based on the atlas
of Paxinos and Watson [68] was selected for semi-quanti-
tative analysis. For estimation of TUNEL-positive cells,
TUNEL positive cells were counted in four consecutive
0.05 mm2 regions of the outer boundary zone of each
medial striatal and cortical infarction. The total number of
TUNEL positive cells with agglutinated nuclei in the four
areas was counted and expressed as cells/mm2 for statisti-
cal analyses. For estimation of Bcl-2 positive cells, two stri-
atal areas (each area: 0.05 mm2) in the ischemic peri-
infarct area and symmetrical two areas in the contralateral
side were analyzed using Scion Image software (Scion
Corp., MD). The areas were captured, binary images cre-
ated with a distinct threshold, then the positive areas cal-
culated and summed up. The ratio of lesion to intact side
was used for statistical analyses. Additionally, confocal
analysis was performed using a Zeiss LSM 510 confocal
Laser scanning microscope.
Statistics
In order to determine significant differences in cerebral
infarcts, motor deficits, the number of TUNEL positive
cells and Bcl-2 positive cells were analyzed using Repeated
Measures of ANOVA followed by post hoc Scheffe's test.
For Bederson neurological deficits, the non-parametric
Kruskal-Wallis test was performed. Statistical significance
was preset at p < 0.05.
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